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Abstract
In all cell types of lung cancer, pleural effusion is a possible complication of disease. 
Paramalignant pleural effusions [PMPE] are not a consequence of malignant disease 
spreading to pleura. The probability that an effusion is paramalignant is higher if the 
effusion is a transudative or parapneumonic effusion. Differentiating between para-
malignant and malignant effusions has both therapeutic and prognostic significance. 
MPEs are a sign of metastatic dissemination of neoplastic disease. In pleural fluid or 
tissue, there are malignant cells. In PMPE, lung cancer had been previously diagnosed. 
Bronchoopstruction, atelectasis, infection, pulmonary emboli, air therapy, and helio-
therapy result in effusion development. PMPEs equally appear in all pathohistological 
types of lung cancer, as MPEs are the most common in lung adenocarcinoma. Also, there 
are biochemical properties of PMPE and MPE. Therapeutic procedures depend on the 
presence of respiratory distress, biochemical properties of pleural fluid, type of primary 
tumour, and expected response to the therapy.
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1. Introduction
Over 175,000 MPE [1] are diagnosed yearly in USA and 50,000 [2] in the UK. In 75% of cases, 
MPE are a consequence of metastatic dissemination of lung or breast cancer [3]. Pleural effu-
sion in lung cancer is a complication of terminal or preterminal stage of disease. Lung cancer 
disturbs one or more mechanisms of normal fluid flow, which is followed by inevitable accu-
mulation of fluid in pleural space. Pleural effusion is not always a sign of cancer metastasis-
ing, but it is evident that in most cases it is related to the primary disease.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Pleural effusion is a possible complication of disease in all cell types of lung cancer [4, 5]. 
At the first presentation, around 15% of patients with lung cancer have a pleural effusion 
[5]. For the duration of disease, approximately 50% of patients develop a pleural effusion. 
Depending on the presence of malignant cells in pleural fluid, pleural effusions are divided 
into two groups: paramalignant pleural effusions [PMPE] and malignant pleural effusions 
[MPE] [3]. Distinguishing between PME and MPE can be challenging. Analytical limitations 
do not allow the use of a single method to pursue the diagnosis and also can expose the 
patients to invasive procedures. PMPE are not a consequence of malignant disease spreading 
to the pleura. The probability that an effusion is paramalignant is higher if the effusion is a 
transudative or parapneumonic effusion. Differentiation between PMPE and MPE is impor-
tant, so that appropriate decisions about treatment modalities can be made, and also due to 
different prognosis of the two conditions.
2. Clinical features of pleural effusion
In patients with lung cancer and pleural effusion, there is a mild to medium symptomatol-
ogy of respiratory distress. Clinical history usually points to the diagnosis of lung, breast, 
ovarian cancer or lymphoma. At the time of diagnosis of malignant pleural effusion, 23% 
of patients are asymptomatic [4]. Pleural effusion followed by pleural pain indicates the 
inflammation of the parietal pleura. Dull pain in the chest wall stirs suspicion of pleural 
malignancy [6]. Nevertheless, pleuritic or dull pain in the chest wall indicates a distortion of 
the parietal pleura and a high probability of an exudative effusion developing. As a rule, pain 
is a consequence of pleural disease. Localisation of pain is correlated to the area of pleura 
that is affected (parietal pleura is innervated by intercostal nerves). Occasionally, pleuritic 
pain spreads into upper parts of stomach [intercostal nerves innervate the abdomen as well]. 
Exception in pain localisation and spreading of the pain are noted when the central parts of 
diaphragmatic pleura are affected by the disease. These parts of the pleura are innervated by 
phrenic nerves and consequently the pain localises to the ipsilateral shoulder. In over 70% of 
patients with MPE intrathoracic pain is a symptom of the disease [7]. Non-productive cough 
can also be a symptom of a pleural effusion. Mechanism of genesis of the cough is not clear 
and is probably related to pleural inflammation. Alternatively, compression of lungs and 
bronchial wall by fluid might stimulate the cough reflex [8]. Cough is present in over 50% 
of patients. A common symptom of pleural effusion is dyspnoea. Dyspnoea is present in 
around 70% of patients with MPE [7]. The severity of dyspnoea is often not proportional to 
the size of pleural effusion [4]. Dyspnoea is usually present in diaphragmatic dysfunction. In 
an inverted diaphragm, dyspnoea is disproportional to the size of the effusion. Mulvey [9] 
classified hemi-diaphragmatic alterations seen on chest radiographs and fluoroscopy into 
three groups. The three groups are: normal function of the hemidiaphragm, fixed hemidia-
phragm, and hemidiaphragm with paradoxical movement. Patients with normal functioning 
diaphragm are usually asymptomatic, even with a large pleural effusion. The second group 
of patients are the patients with a fixed hemidiaphragm. Immobile diaphragm disables suffi-
cient ventilation of the lungs. In the third patient group, hemidiaphragm exhibits paradoxical 
movement which results in severe dyspnoea. Paradoxical movement of the right hemidia-
phragm is rarely seen, probably due to proximity of the liver. The severity of respiratory 
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insufficiency depends on the size of the effusion and previous lung function. Pleural effusion 
reduces the thoracic space and lung volumes or in turn the thoracic cavity enlarges as the 
ipsilateral hemidiaphragm descends. Therefore, fluid in the pleural space causes restrictive 
ventilator defect. Small to moderate pleural effusions cause dislocation rather than lung com-
pression and they have a little consequential effect on the lung function [6]. In massive pleural 
effusions, the most common symptoms are the ones that are a direct consequence of lung 
function compromise. Improvement of lung function after therapeutic thoracocentesis is less 
than expected [10]. Explanation of inadequate improvement of lung function probably lays in 
the fact that usually, besides pleural effusion, there are also changes in the lung parenchyma. 
In massive pleural effusions, the mechanism of dyspnoea is closely related to the reduction 
of chest wall compliance, counter lateral mediastinum movement, and loss of the ipsilateral 
lung volume with additional action of neurogenic factors of the pulmonary parenchyma [11].
In 26 patients, spirometry was performed before thoracocentesis and 24 hours after thoracocen-
tesis. Average amount of evacuated fluid was 1740 ml [12]. After thoracocentesis, vital capacity 
increased for 410 ± 390 ml. Estenne et al. [13] examined respiratory mechanics in nine patients, 
before and 2 hours after evacuation of 600–2750 ml (average amount = 1818 ml) of pleural fluid. 
Before thoracocentesis, forced vital capacity (FVC) was between 22 and 51% of predicted val-
ues. After thoracocentesis, the average value of FVC has increased only by 300–460 ml. Estenne 
interprets reduction in dyspnoea by reduction in the size of the thoracic volume. Reduction of 
the thoracic cavum enables inspiratory muscles to function in much more favourable length-
tension relationship. Before thoracocentesis, maximum inspiratory pressure at TLC (total lung 
capacity) was −16 cm H
2
O, and after thoracentesis, the pressure fell to −25 cm H
2
O. Explanation 
of these phenomena probably lays in the fact that hemidiaphragm is released from the pressure 
of pleural fluid. In pleural effusion, PaO
2
 is usually low, as alveolar-arterial gradient is increased.
Patients with pleural effusion complain of intolerance to exertion. Exertional intolerance was 
examined in 24 patients, before and after thoracocentesis. There were no significant changes 
in hypoxia and hypercapnia level. A number of patients had malignant effusions and it is pos-
sible that the given results are the consequence of primary disease rather than lung function 
being compromised by pleural effusion [14].
Systemic symptoms are a consequence of cancer development. The most common systemic 
symptoms are weight loss, general weakness, haemoptysis, fever, cyanosis, and dysphagia [4]. 
Over 40% of patients had systemic symptoms, general weakness, and loss of weight. Eighteen 
percent of patients had fevers, and 9% of patients had haemoptysis [13]. Similar data were 
found by Chernow, Sahn [4] and Baburao and assoc. [15]. The patients with MPE had chest 
pain in 32% cases, compared to 11% of patients with benign effusions, while the patients with 
benign effusions were more commonly found to have pleuritic pain [51 versus 24%]. Fever 
was more common in the patients with benign effusion (73 versus 37%) [8].
Massive pleural effusion can compromise cardiac function. It has been proven that massive 
pleural effusion can lead to the right ventricular diastolic collapse with consequential reduc-
tion of cardiac output. In artificial bilateral pleural effusions, right ventricular diastolic col-
lapse appears at the pressure of about 4 mmHg [16]. This value of pleural pressure is also 
seen with the patients with massive pleural effusion [17]. Arterial-blood gases usually have 
clinically acceptable values.
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On examining the patient, the absence of the pectoral fremitus, shortened and dull percussion 
sound, and weakened respiratory sounds are usually found. By auscultation above the fluid 
level, the change of breathing pattern (area of the compromised lung), that is, aegophony is 
heard. Conversing through auscultation of the affected side, increased resonance of voice 
can be heard. Experienced doctors think that dullness to percussion and aegophony are two 
most common findings that are present in over 90% of patients with pleural effusion. Above 
the area of dullness to percussion, humid sounds are heard ausculatorily [18]. Contralateral 
displacement of the trachea could be found in massive effusion.
3. Paramalignant pleural effusion
The main characteristic of PMPE is that the lung cancer had been previously diagnosed, and 
that malignant cells had not been identified in the effusion either cytologically or pathohis-
tologically. These effusions are not a sign of malignant disease spreading to the pleura [3].
PMPEs are a direct consequence of local or systemic effect of tumour. Pulmonary infection 
distally from partial or complete obstruction of bronchi could be a cause of parapneumonic 
effusions. Obstruction of main or lobar bronchi by neoplasm leads to consequential atelec-
tasis of the corresponding part of the lung. In order to compensate for the lost volume, the 
remainder of the lung must additionally expand or the hemithorax must be contracted. This 
sequence of events results in lower intrapleural pressure. Low intrapleural pressure is an 
additional factor of more intensive fluid accumulation.
Furthermore, the incidence of pulmonary emboli in malignant disease is not negligible, 
and pulmonary embolus can also be one of the causes for pleural effusion development. 
Additionally, certain chemotherapeutic protocols are a cause of increased retention of fluid 
in pleural space. Lymphatic obstruction is a common property of lung cancer and lymphoma 
and at the same time is a possible complication of radiotherapy which is a contributing factor 
of fluid accumulation in pleural space.
A considerable number of patients with malignant disease are malnurtured. Hypoproteinemia 
can in rare cases lead to transudative pleural effusion. In malignant disease, metastatic 
changes on the pericardium can be found. Pericardial effusion leads to the increase of hydro-
static pressure in systemic and pulmonary circulation which leads to transudative pleural 
effusion development [19].
In around 5% of patients with lung cancer, PMPEs are diagnosed. Frequency of PMPE in 
squamous cell carcinoma is 4.5%, in adenocarcinoma 6.2% and in SCLC 6.5%, so they are 
equally present in all pathohistological types of lung cancer [7, 21].
In 67% of patients, PMPEs are moderate or massive. They are mostly serous or cloudy (60%), 
and haemorrhagic effusions represent 21.3% of all PMPEs [7, 20].
3.1. Pleural fluid analysis
Compared to the MPE ratio of LDH—E/S (effusion/serum) is higher in PMPE, but not signifi-
cantly higher. This can be interpreted with the help of the fact that in PMPE, parapneumonic 
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effusion (inflammation is followed by high values of LDH in effusion) is diagnosed in 18.3% 
of patients. Significant differences in other biochemical characteristics (glucose, proteins, and 
cholesterol) were not found either [7].
Compared to MPE, total number of cells, eosinophils, and PMN [polymorphonuclear cells] 
is higher in the group of patients with PMPE, but not significantly. Lymphocytes and PMN 
dominate in the differential picture in PMPE. Percentage of PMN is usually below 25%, but 
cases when they dominate are not rare, for example, in secondary pleural inflammation. In 
PMPE, eosinophils are found in 51% of patients diagnosed with PMPE. The percentage range 
of eosinophils in pleural fluid ranged from 1 to 24% [7].
3.2. Management of paramalignant pleural effusion
PMPEs are not an absolute contraindication for operative treatment. It is a therapeutic chal-
lenge to establish the optimal therapeutic protocol for the patients who are diagnosed with 
lung cancer and ipsilateral pleural effusion in which no malignant cells are found cytologi-
cally. Rodriguez-Panadero [21] performed thoracoscopy on 21 patients with lung cancer and 
paramalignant effusion. After thoracoscopy, thoracotomy was indicated in five patients. 
Invasion of mediastinal lymph nodes was found in all five patients. In another study, five 
patients out of 73 with PMPE have survived long term after surgery [22]. It can be concluded 
that in the patients with PMPE, thoracoscopy and CT of the thorax should be firstly done 
for the evaluation of mediastinal lymph nodes. In the case of enlarged lymph nodes, medi-
astinoscopy is indicated. In the patients with negative thoracoscopy, even if lymphatics are 
not enlarged, explorative thoracotomy is recommended. Before resection, lavage of pleural 
space with cytological analysis of the obtained material should be performed. One study 
that encompassed more than 1200 patients found that in patients with lung cancer without 
an effusion undergoing surgical resection with curative intent, 5.3% of patients had positive 
cytological findings of the pleural fluid lavage at the time of thoracotomy before surgical 
resection took place [23]. In PMPE, most commonly performed therapeutic procedures are 
thoracocentesis (51%) and pleurodesis (39%). Thoracotomy was done in two (6%) patients [7].
4. Malignant pleural effusion
Malignancy is the most common cause of massive pleural effusions opacifying the entire 
hemithorax and of large pleural effusions opacifying two thirds of a hemithorax. MPE is an 
end-stage sign of malignant disease. Sometimes MPE can be the first clinical sign of a tumour, 
given that often lung cancer are not detected in the beginning of disease development. In 
a retrospective series of 766 patients, carcinoma was the cause of 55% of massive and large 
pleural effusions [24]; other causes included tuberculosis effusion and pleural empyema.
In older age groups (>60 years old), malignant pleural effusions are the most common cause 
of exudative effusions and they are often the first clinical manifestation of disease (Figure 1) 
[3, 5]. Diagnosis of malignant effusion is established by the identification of malignant cells 
in effusion or pleural tissue. Pathohistological and/or cytological investigations are not of 
credible diagnostic significance until malignant cells are defined.
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In over a half of MPE in men, the effusion is caused by lung cancer. MPEs appear in all cell 
types of lung cancer [3]. Incidence of MPE in lung adenocarcinoma is significantly higher in 
comparison to other pathohistological types of cancer. Thirty one percent of patients (out of 
96) with lung adenocarcinoma developed a MPE, while 8.6% of patients (out of 404) with 
squamous cell carcinoma and between 7 and 10% with patients with small-cell carcinoma 
developed a MPE [7, 25–27].
The next most common causatives of malignant effusions are lymphoma and leukaemias 
(20%). Seven percent of MPE are a result of spread of gastrointestinal system cancer, 6% of 
genitourinary system and 11% of tumour are of unknown primary source [28]. Incidence of 
MPE in regards to primary tumour localisation is given in Table 1.
In women, around 40% of MPE is a direct consequence of spread of breast cancer. In about 
50% of patients with breast cancer, pleural effusion is developed during evolution of disease 
[29]. Twenty percent of effusions are the consequence of genital tract tumour spread, 15% of 
lung malignoma, 8% of lymphoma or leukaemia, 3% of melanoma, and 9% of tumours of 
unknown primary source.
Primary tumour localisation Incidence %
Breast 26–49
Lung 10–24
Lymphoma Up to 24
Non-Hodgkin lymphoma 13–24
Ovary 6–17
Hodgkin’s disease Up to 13
Table 1. Causes of malignant pleural effusions.
Figure 1. Pleural fluid sample containing cells of adenocarcinoma. N.B.—Origin of the primary tumour is unknown.
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4.1. Pathophysiology of malignant pleural effusions
Malignant tumours can lead to pleural effusion development either by direct or indirect 
spread of the disease. In post-mortem studies, malignant disease of the pleura without an 
effusion was found in 40% [30] to 45% [6] of cases. Pleural effusions in malignancy most 
likely develop due to increased entry of fluid into pleural space and decreased evacuation of 
liquid from the pleural space. Increased transport of liquid into pleural space occurs due to 
increased permeability of the pleural vessels by direct invasion of the tumour cells, vasoactive 
and inflammatory cytokines. Increased permeability of pleural vessels can also be caused by 
injury, infection, pulmonary embolus, pulmonary infarction that causes movement of liquid 
from lung to pleural space by increased hydrostatic forces caused by venous obstruction [31].
Pleural liquid and protein are largely resorbed by the lymphatic system of the parietal pleura. 
The exit of fluid from pleural space could be decreased by several mechanisms that reduce 
lymphatic drainage. Lymphatic obstruction at any point, from the stomata of parietal pleura 
to mediastinal lymph nodes is a dominant cause of increased accumulation of pleural fluid 
[3, 20]. Insufficiency of lymphatic drainage appears for two reasons. The first one is that the 
transport of liquid from pleural space through stomata and lymphatic vessels of parietal 
pleura is disabled because of the presence of metastases and other reason, as the lymphatic 
vessels of parietal pleura are mostly drained by mediastinal lymph nodes. So, neoplastically 
changed mediastinal lymph nodes decrease the clearance of pleural cavum thus contributing 
to additional accumulation of fluid [32]. Obstruction of thoracal ductus by malignant tumour 
can also be a cause of pleural effusion development. In these cases, a chylothorax develops. 
Chylothorax is the most common complication of mediastinal tumours, mostly lymphoma 
(in 50%). Furthermore, chylothorax is a complication of surgery (20%) and trauma to the 
thorax (<5%) [33].
In atelectasis pleural pressure is lower due to bronchial obstruction and therefore the exit of 
fluid from pleural space is reduced. In superior vena cava syndrome, pleural liquid drainage 
is reduced due to elevated central venous pressure.
Cellular and molecular mechanisms of localisation of pleural metastases are still mostly 
unclear. From visceral pleura malignant cells spread to parietal pleura, where they multiply 
[20]. Pleural metastases are also found on visceral and parietal pleura, while isolated metasta-
ses of parietal pleura have never been identified. From visceral pleura, malignant cells spread 
on parietal pleura [3]. In the process of pleural metastase development, several steps are 
necessary. First, malignant cells must leave the primary tumour. For this step, deregulation 
of cellular adhesion is necessary. Deregulation of cellular adhesion depends on the changes 
in the extracellular matrix and the change of expression degree of integrin with simultane-
ous increase of cell motility. By leaving the primary tumour, tumour cells via vascular or 
lymphatic structures (they can cause different haemodynamic and immunological changes 
in these structures) find their way towards distant organs or lymph nodes. With the help of 
video microscopy, it has been shown that a great number of circulating tumour cells (80%) 
stay alive even up to 3 days after their entry, both into circulation and/or extravascular space. 
Only small subgroups of cells (0.07%) can form metastases [34].
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Control of extravascular cell growth is crucial in forming of metastases. Formation of pleu-
ral metastases is probably mediated by the interaction of mesothelial and neoplastic cells. 
Tumour activated mediators (VEGF, ligand for CC-sequence of chemokines CCL2 and TNF) 
stimulate the accumulation of inflammatory cells [35, 36]. IL-5 stimulates the development 
of MPE, accumulation of Eo as well as myeloid suppressor tumour-activating cells [37]. On 
the other hand, tumour cells activate proinflammatory and proangiogenic transcription 
programs controlled by nuclear transcription factor (NF)-kB [38] and signal transduction of 
transcription activator (STAT)3 [39]. Tumour necrosis factor (TNF), interleukin 6([IL-6), and 
osteopontin (OPN) participate in positive reverse coupling (povratna sprega) regulating the 
activation of tumour NF-kB/STAT3. The end result of these events is the formation of MPE 
[35]. Furthermore, stimulated mesothelial cells secrete different factors, such as chemoattrac-
tants, chemokines, and platelet-derived growth factor (PDGF). These products facilitate the 
appearance of metastases. Simultaneously, the production of adhesion molecules is increased, 
such as intracellular adhesive molecules [ICAM-1] and vascular molecules of cell adhesion 
(VCAM-1) which, in vitro, in contact with cancer cells secrete metalloproteinase [40].
And finally, continuous growth of metastatic foci depends on angiogenesis. Vascular endo-
thelial growth factor (VEGF) stimulates proliferation and migration of endothelial cells. At the 
same time, invasion of pleural space by malignant cells and VEGF expression from tumour 
cells is necessary for the formation of pleural liquid [41]. Angiogenesis is the primary process 
that disables the growth and progression of tumour [42]. Yano et al. [41] used human cells 
of pulmonary adenocarcinoma and squamous cell cancer, with different invasive properties 
and different levels of VEGF expression, and they have proven that invasion of pleural space 
by malignant cells and VEGF expression from tumour cells is necessary for the formation of 
pleural fluid. VEGF is one of the most powerful known chemokines that directly affect the 
increase of vascular permeability [42]. In comparison to tuberculosis effusions and transuda-
tive effusions, the concentration of VEGF is significantly higher in malignant effusion [42, 
43]. The average value of VEGF in malignant pleural effusion is significantly higher than in 
pleural effusions that are a consequence of congestive cardiac failure [41].
Malignant effusion in comparison to benign incidence of CD4+ cells is significantly increased 
[44]. Accumulation of immunosuppression and protumour CD4+ lymphocytes contributes to 
weakening of the immune response and simultaneous growth of tumour cells [45].
On development of pleural metastases, tumour cells disseminate onto the mesothelial surface 
or malignant cells penetrate the subserosa. When the mesothelium is encompassed by the 
tumour, ‘excess’ of tumour cells appears in the pleural fluid. However, when only subme-
sothelium is infiltrated by the tumour, there is a small number of malignant cells in pleural 
liquid. In these cases, malignant cells are rarely identified in pleural fluid, that is, thoracocen-
tesis does not have any diagnostic significance [46, 47]. Infiltration of pleura by tumour results 
in reactive changes of mesothelium, that is, fibrosis. In advanced stage of disease, disposal of 
collagen into submesothelial pleural tissue is increased, which is at least a part of the cause of 
low values of pH and glucose in the effusion.
Another, and less likely mechanism of metastases development is by direct invasion of pleura 
by tumour, whether it is lung or breast cancer. In some cases, spread of tumour to the pleura 
is evident, and in spite of this, the effusion does not develop. For example, effusion rarely 
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appears when pleura is invaded by sarcoma. One of the properties of sarcoma is the absence 
of lymphogenic metastases [20].
Bilateral metastases in lung cancer are usually indirect evidence of the primary neoplasm 
spreading to the liver and of subsequent disease dissemination to the lungs. However, if the 
lungs are not the primary source of carcinoma, this implies that the changes on pleura are a 
tertiary consequence of metastasis spreading from the liver [4, 19].
4.2. Pleural fluid analysis
Pleural effusions in lung cancer are usually classified as exudates [4, 48]. In 5–10% of cases, the 
pleural effusion is a transudate [4, 54]. Transudative effusions are more likely when the lym-
phatic drainage is obstructed by the tumour and in atelectasis caused by bronchial obstruc-
tion or congestive cardiac failure [31]. Malignant cells can be found in transudative effusions 
as well. Macroscopic MPEs can be serous, serosanguinous, and haemorrhagic. Erythrocyte 
count in pleural fluid is often between 30,000 and 50,000/μl [48]. Erythrocyte count over 
100,000/μl, in the absence of trauma, indicates a probable diagnosis of malignant disease. 
Direct invasion of blood vessels, occlusion of venules, increased permeability of capillaries 
due to vasoactive chemokines and cytokines, occlusion of venules usually result in a bloody, 
malignant pleural effusion.
In more than half of malignant effusions, lymphocytes are present in 50–70% range, but are 
typically present in lesser amount than they occur with tuberculosis pleurisy (usually ≥80%) 
[12, 49]. In TBCPE, the number of lymphocytes was 153,696 × 104 versus 95,414 × 104/ml in 
MPE [7]. In order to differentiate between tuberculosis and malignant effusions, determining 
adenosine deaminase (ADA) presence in the effusion is of significance. The level of ADA 
greater than 70 U/l in effusion indicates to tuberculosis aetiology, while the ADA level below 
40 U/l excludes the tuberculosis aetiology [50, 51]. Although the cause of lymphocytosis is 
unclear, the lymphocytes that are most prevalent are T lymphocytes that have a role in local 
defence systems against tumour invasion of the pleural cavity. In vitro, lymphocytes of malig-
nant pleural effusions spontaneously secrete lymphokines [52]. Mesothelial cell percentage 
in malignant effusion varies ranging from few percent to a large percentage of total cells. 
Mesothelial cell abundance occurs early in the course of infiltration of the pleura, well before 
pleural fibrosis and marked tumour infiltration. Fewer mesothelial cells are seen in advanced 
stages of pleural metastases due to pleural fibrosis.
The percentage of PMN is usually below 25%, even though often PMN can dominate the 
percentage, as in secondary inflammation of pleura. Eosinophils are present in up to 36% 
of malignant effusions [7]. The percentage in which eosinophils are a significant finding in 
pleural liquid is considered to be higher than 10%. In MPE, eosinophil percentage ranges 
from 1 to 52% [7]. Eosinophilic pleural effusion is the most common in malignant disease (34, 
8%) [24], which is then followed by infections (19, 2%), effusions of unknown aetiology (14, 
1%), post-traumatic effusions (8, 9%), and effusions (23%) in other diseases.
Usually, eosinophilia is related to the presence of blood or air in pleural space. Eosinophilic 
effusions reappear even after repeated thoracocentesis [53]. Good correlation was found 
between IL-5 levels and the number of eosinophils in pleural fluid [54]. In MPE, compared to 
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other cells, malignant cells are rarely found. Significant concentrations of proteins are found 
in pleural fluid. Nevertheless, the total amount of protein transported from pleural space is 
lesser than the amount of protein transported in tuberculosis effusions, effusions in pulmo-
nary embolism, and congestive cardiac failure.
Chronic pleural effusions (CPE) are very rarely found to be transudates. Characteristic bio-
chemical property of CPEs is that they have low pH and low glucose concentration, while 
they have a large protein concentration. The ratio of pleural protein to serum protein can 
found to be low, and nevertheless, the effusion would still be classified as an exudate. If in 
exudative effusion only the LDH criterium is positive, this points to the diagnosis of malig-
nancy [48, 55, 56].
In one third of MPE, pH is less than 7.30 (ranging from 6.95 to 7.29) [57]. Effusions with low 
pH value have a high concentration of glucose (<60 mg/dl) and pO
2
, and additionally a high 
concentration of lactate and pCO
2
. Glucose concentration can be rarely reduced to the value 
of 5 mg/dl and it usually ranges from 30 to 55 mg/dl [55]. Malignant effusions with low values 
of pH and glucose characteristically have a longer evolution of up to several months and they 
usually follow the fast tumour and pleural fibrosis [54]. Pathologically altered pleura reduce 
glucose entry into the pleural space and at the same time disable the transport of metabolic 
products. The end result of this disorder is local acidosis [56]. Low level of LDH in effusion 
indicates a higher possibility of negative pathohistological results. In effusions with high 
LDH level, the percentage of positive biopsies is higher [58].
Pleural fluid amylase concentration is found to be elevated in 10% of patients diagnosed with 
a MPE. However, the origin of amylase in pleural fluid is not pancreatic but is found to be 
salivary instead. In a series of consecutive effusions, a very high amylase level in malignant 
pleural fluid (>600 IU/L) was found to be a poor prognostic factor [59].
4.3. Tumour markers in pleural liquid
Biological markers of malignancy are yet to be identified, but may be identified in the future 
as the molecular biology of cancer is better understood. Pleural fluid biomarkers could poten-
tially assist the cytological diagnosis. Unfortunately, biomarkers have been found to have 
indeterminate specificity and sensitivity which has led to overlap between malignant and 
benign conditions. An approach that has been used is to combine the tumour markers to 
improve the diagnostic yield. However, the diagnosis of malignancy can also be reached by 
using the clinical characteristics—duration of symptoms for more than a month, absence of 
fever, CT thorax findings of malignancy, and serosanguinous fluid [60].
4.3.1. Carcinoembryonic antigen
It has been concluded in several reports that determining the CEA level in pleural fluid is useful 
in establishing the diagnosis of malignant pleural effusion [61, 62]. CEA level below 10 ng/ml 
is usually found in lymphoma, sarcoma, and mesothelioma. CEA higher than 10 ng/ml could 
indicate a malignant disease; however, it does not have diagnostic significance, and routine 
measuring of CEA is not recommended.
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4.3.2. Carbohydrate antigen
It is known that three different carbohydrate antigens (Ca 15-3, CA 19-9, and CA 72-4) are 
present in malignant disease. These antigens have been studied in order to differentiate 
malignant and benign effusions [63]. Comparing the levels of these three antigens in malig-
nant and benign effusions, there is a significant overlap of the obtained results. Hence, this 
test is not sensitive enough and it is not used in routine diagnostics.
4.3.3. Sialyl stage-specific antigen-1
Sialyi stage-specific antigen-1 is a carbohydrate antigen present in malignant disease. Patients 
with positive cytological findings of pleural fluid to adenocarcinoma cells have higher val-
ues of this antigen in effusion in comparison to effusions of other aetiologies [64]. However, 
simultaneously, significant overlap of value levels of this marker was recorded, and therefore 
sialyl stage-specific antigen-1 in effusions of unclear aetiology does not bare a diagnostic 
significance.
4.3.4. Cytokeratin-19 fragments
Cytokeratin 19 (CYFRA 21-1) is the main component of cytoskeletal filaments of epithelial 
cells. It is significantly increased in malignant diseases. The level of CYFRA-21 higher than 
100 ng/ml is present in around 60% of patients with carcinoma and mesothelioma [65]. A 
significant overlap has been found in CYFRE levels in both malignant and benign effusions, 
and therefore this test is not recommended in routine work.
4.3.5. Enolase
Enolase is a glycolytic enzyme present in extracts of neuroendocrine tumours. In pleural effu-
sions in small cell lung cancer, higher levels of enolase are found when compared to pleural 
effusions in non-small cell lung cancer and benign effusions [66], but as there is a significant 
overlap in measured enolase values establishing its presence has no diagnostic significance.
4.3.6. Squamous cell carcinoma antigens
Squamous cell carcinoma antigen (SCC) has been used as a serum marker for squamous cell 
carcinoma. In the greatest number of patients with pleural effusion in malignant disease, a 
low level of this marker was found. This marker was positive in 7 out of 11 patients (64%) 
with squamous cell carcinoma. However, SCC values are very high in some benign effusions 
as well; thus, SCC is not used in squamous cell carcinoma diagnostics [66].
4.3.7. Oncogenes
Oncogenes are closely related to the development of malignancy, and one of the hypotheses 
has suggested that in the pleural fluid of patients with pleural malignancy cells containing 
oncogenes are present. In 11 (34%) of malignant effusions, protein p53 has been detected, and 
should be noted that it has not been found in any non-malignant effusion [67].
Pleural Effusions in Lung Cancer: Detection and Treatment
http://dx.doi.org/10.5772/intechopen.78307
53
There is no significant difference in CMYC oncogene expression between malignant and 
benign effusions [68]. CHARAS oncogene has been detected in 21 out of 24 malignant effu-
sions, but it has also been found in 6 out of 16 benign effusions (37%), and therefore its diag-
nostic utility is limited [69].
4.3.8. Hyaluronic acid
Pleural fluid of patients with mesothelioma is sometimes extremely viscous. Increased 
viscosity of liquid is a consequence of hyaluronate, that is, hyaluronic acid presence. 
Hyaluronic acid level higher than 1 mg/ml indicates mesothelioma diagnosis. In no other 
aetiology of pleural effusion, hyaluronate level higher than 0.8 mg/ml was found. Sensitivity 
of this test for malignant mesothelioma is 56% [70]. Average values of hyaluronic acid in 
mesothelioma are comparable to values of hyaluronic acid present in pleural effusions in 
adenocarcinoma [71].
4.3.9. Lectins binding
Lectins are a class of glycoproteins of non-immune origin which bind specifically to the carbo-
hydrate group in different biological products. Lectin binds much easier to adenocarcinoma 
cells compared to reactive mesothelial cells or mesothelioma cells [72]. These authors could 
not find significant differences in lectin binding between mesothelioma cells and reactive 
mesothelial cells.
4.3.10. Flow cytometry
Flow cytometry is a method of quick measuring of nuclear DNA. It has been postulated 
that this method would enable differentiation of benign from malignant cells, taking into 
account that malignant cells have numerous chromosomal abnormalities (aneuploidy) and 
consequentially abnormal DNA content (DNA aneuploidy). However, aneuploidy is present 
in benign effusions as well [73]. Flow cytometry is used in the identification of superficial 
lymphocyte markers and it has found the use in diagnosis of lymphoma [68].
4.3.11. Chromosomal analysis
Malignant cells have a higher number of chromosomes with structural abnormalities, such as 
translocation, ascension, dissension, discention, inversion, and isochromosomy [70]. The place 
of chromosome analysis in routine examination of pleural effusions remains to be established.
4.3.12. Association of mRNA expression in metastatic malignant effusions
Alternative diagnostic methods are still needed to assist in the diagnosis of pleural effusions. 
The supernatant of samples of pleural effusion might contain useful information such as 
nucleic acids and proteins. MicroRNAs that are circulating and cell free have been identified 
as potential biomarkers of cancer. MicroRNAs are heavily involved in processes of develop-
ment, cell survival, carcinogenesis, and apoptosis. Hence, it is likely that they play a consider-
able role in modulating sensitivity and resistance to anticancer medications [74].
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However, potential applications and the existence of cell-free microRNA in pleural effusion 
samples are uncertain. MicroRNA (miRNA) is a group of short RNAs that regulate expression 
of proteins post-transcriptionally by binding to the 3’UTRs target mRNAs. As MicroRNAs are 
involved in cancer development, the expression of a specific miRNA profile may suggest the 
disease status, prognosis, and response to chemotherapy agents.
Wang et al. [75] have used real-time quantitative PCR to analyse related gene expression in 46 
patients with malignant effusion. Data were prospectively collected from gastric cancer, non-small 
cell lung cancer, and gynaecological cancer patients. Cancer cells that are viable and obtained 
from malignant effusions are tested for sensitivity to docetaxel and cisplatin using ATP-TCA 
assay. The authors have concluded that BRCA1 (breast cancer susceptibility gene 1) and ERCC1 
(excision repair cross-complementing group 1) miRNA expression levels are in correlation with 
in vitro chemosensitivity to docetaxel and/or cisplatin in malignant effusions of gastric cancer and 
non-small cell lung cancer patients. Additionally, combining ERCC1 and BRCA1 may produce 
better results predicting the sensitivity to cisplatin than when only a single agent is considered.
4.4. Prognosis of malignant pleural effusion
By diagnosing a malignant effusion, prognostic information is obtained simultaneously [57]. 
Mean survival time of patients with lung cancer and MPE is between 3 and 4 months [76]. 
Multivariable analysis has demonstrated that shorter survival time was found in patients 
with a high level of serum CRP, low values of albumins, serum proteins, distant metastases 
and those patients who did not have chemotherapy [77]. Disease progression and poor prog-
nosis can be related to the immunosuppressant effect of tumour and functional damage of the 
immune system.
In non-small cell carcinoma, mean survival time in patients with stage IIIb, IIIb with pleural 
effusion and stage IV was 15.3, 7.7, and 5.5 months, respectively [78].
From the time malignant, effusion is diagnosed, patients with lung, stomach, and ovarian 
cancer survive for only several months, while survival time in patients with breast cancer is 
longer—several months or years, depending on the response to chemotherapy [4, 55]. Survival 
time of the patients with lymphomatoid effusion is between the survival time of patients with 
breast cancer and cancers of different organs.
Prognosis of malignant effusion depends on the stage of the disease and contributing factors 
(Table 2) [55], which is of crucial importance for choosing the treatment modality. LDH cri-
terium and pleural fluid pH in malignant effusions are important prognostic indicators. Poor 
prognosis is indicated by high LDH effusion/serum ratio, high level of LDH in effusion, and 
low pH of pleural fluid [55]. When pH and glucose levels are found to be low in a malignant 
pleural effusion (below 7.30 and 60 mg/dl, respectively), the survival time is found to be less 
for an average of 2 months when compared to those patients who have normal values of 
glucose and pH-average of 10-month survival time [76].
The only true predictive marker of mortality might be the performance status at the time of 
diagnosis. A Karnofsky score of more than 70 is associated with a median survival time of 
13.2 months, while a Karnofsky score of less than 30 is associated with a median survival time 
of 1.1 months.
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4.5. Imaging
4.5.1. Chest radiographs
For documenting the presence of pleural fluid in pleural space, the most practical diagnostic 
test is conventional chest radiography [79]. Pathological changes of the pleura are commonly 
easily diagnosed by appropriate radiological modalities.
The distribution of fluid in pleural space is completely dependent on the laws of gravity. 
Fluid is firstly accumulated in basal parts of the hemithorax, that is, between the lower sur-
face of the lung and diaphragm. When a large amount of fluid accumulates, the fluid starts 
spreading to anterior, posterior, and lateral costophrenic sinuses. The thickness of the fluid is 
greater laterally. The line of the border discretely fades on moving medially and ends in the 
mediastinum with a meniscus shaped line. On lateral radiographs, upper border of pleural 
fluid is semicircular, that is, the upper border is higher both anteriorly and posteriorly, while 
it gently descends in the middle part. A small amount of fluid seen on the chest radiograph is 
not indicative of a pleural effusion, as the diaphragmatic configuration is unchanged. During 
accumulation of a larger amount of pleural fluid, costophrenic angles are the first to be filled. 
Costophrenic angles are filled only after the quantity of fluid in sub-pulmonary space exceeds 
175 ml s.
‘Middle lobe step sign’ can be often seen on a lateral view. The ‘middle lobe step sign’ is 
explained by the fact that the fluid firstly accumulates in the lower lobe, as it is the lowest 
of the pulmonary lobes. The middle lobe remains unchanged and its volume is preserved. 
Pleural fluid is most commonly evident in the posterior parts of the chest.
In massive pleural effusion, the sheer weight of the fluid can be a cause of inverted dia-
phragm, so much so that the normal convex appearance becomes concave. Inversion of the 
hemidiaphragm is more commonly seen on the left side. On diascopy of the inverted dia-
phragm, paradoxical movements are evident, that is, it rises on inspiration and descends on 
expiration [9].
Tumour related Non-tumour related
Extensive invasion of mediastinal lymph nodes Tuberculosis or fungal infection
Parapneumonic effusion (obstructive pneumonia) Immunological disorders: rheumatic, allergic, etc.
Pericardial effusion as a consequence of malignant 
disease
Pulmonary embolism
Previous mediastinal radiotherapy Congestive cardiac failure
Malignant ascites Parapneumonic effusion as a consequence of an unrelated 
pneumonia
Pulmonary embolus Organ failure that is not a consequence of cancer or cancer 
treatment
Table 2. Factors contributing to the spread of pleural effusion.
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It is common practice for the chest radiographs to be performed while the patient is standing. 
However, in critically ill patients, the chest radiographs can be only performed while the 
patient is lying down, and this could lead to the pleural effusion not being diagnosed. This is 
due to the fact that pleural fluid is being pulled by gravity and consequently localises in the 
posterior parts of the thoracic cavity.
Characteristic signs of a pleural effusion on chest radiograph when the patient is lying down 
are: blunting of the costophrenic angle, increased density of the part of the lung, loss of dia-
phragmatic silhouette, the presence of apical cap, elevation of a hemidiaphragm, difficulty in 
spotting vascular structures of the lower lobe, and accentuated small fissure [80]. These signs 
are not present in patients with a small or moderate pleural effusion.
Serial radiographs of the chest while the patient is lying down after moving the patient from one 
side to the other side can indicate a presence of mobile fluid and absence of loculations which in 
malignant pleural effusions enables the determination of a possible pleurodesis site [81].
Using the above mentioned radiological signs, it is possible to differentiate increased density 
of a pleural effusion from infiltrates for example. First, if the cause of increased density is a 
pleural effusion vascular structures of the lung will be visible on the radiograph. Any other 
intra-pulmonary process would cause an obliteration of vascular structures—‘the silhouette 
effect’. Second, if pleural effusion is the cause of increased density, the visible change will 
be entirely homogenous. Infiltrates caused by an intrapulmonary process are usually less 
homogenous. Third, air bronchogram is only present when the increased density is a conse-
quence of parenchymal infiltration.
Typical localization of fluid in pleural space of healthy lungs depends on the reverse action 
of elastic forces. Compared to other parts of the lung, the parts of the lung that are below 
the effusion exhibit different characteristics of elastic forces. Part of the lung above which 
the fluid is accumulated has a higher intensity of action reverse elastic forces. Accordingly, 
atypical localisation of fluid in the pleural space indicates that the part of the pulmonary 
parenchyma below the effusion is altered. Encapsulated fluid usually produces an image of 
a bi-convex lens or adopts a lenticular shape. For instance, if lower lobe pathology increases 
the intensity of action of reverse elastic forces, the fluid will accumulate posteriomedially. 
Characteristically, the opacity is higher in the axillary line. In some cases, a pleural effusion 
can mimic middle or lower lobe atelectasis. On the lateral radiographs, the upper border of 
the density is parallel to the main fissure and is higher in the posterior segments of the thorax, 
and on moving anteriorly, it descends into the costophrenic sulcus. Lobar or segmental lung 
collapse can be a cause of pleural effusion development. In these cases, the effusion can mimic 
pleural adhesion [82].
When the whole hemithorax is opacified, the first priority should be to determine the position 
of the mediastinum, as the position of the mediastinum depends on the intrapleural pressure. 
Lower intrapleural pressure will shift the mediastinum to the ipsilateral side of the effusion, 
(Figure 2) while if the pressure is higher on the side of the effusion mediastinum will shift con-
tralaterally, (Figure 3) assuming that the mediastinum is not infiltrated by a tumour or an infil-
trative process, that is, that it is not fixed. When the mediastinum is fixed, there is no mediastinal 
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Figure 2. Atelectasis of the left lung with ipsilateral shifting of the mediastinum.
Figure 3. Massive pleural effusion with contralateral shifting of mediastinum.
shift seen. If the mediastinum shifts to the ipsilateral side of the effusion, it can be concluded 
that the underlying process is an expansive lung disease. Occasionally, in complete atelectasis 
contralateral lung is a cause of increased retrosternal light, which is clearly seen on a lateral 
radiograph. This radiological picture corresponds to complete obstruction of the ipsilateral 
bronchus by a neoplasm. In obstruction of a bronchus, thoracocentesis is not indicated as it is 
not necessary for diagnostic work up and as it carries a risk of additional increase of the negative 
intrapleural pressure. Possible complications include pneumothorax and re-expansive pulmo-
nary oedema. In an obstructive lesion, evacuation of a large amount of fluid [more than 1000 ml] 
is only recommended if a simultaneous measuring if intrapleural pressure is possible [17].
4.5.2. Computed tomography [CT]
CT is efficient in diagnosing pathological alterations of the pulmonary parenchyma and changes 
that belong to pleural diseases (Figure 4). In comparison to standard radiography, pleural 
alterations are diagnosed much easier on the CT scan and are easily distinguished from the 
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pulmonary parenchyma and diseases that do not affect the pleura [83]. Collections of fluid or 
masses have a tendency to adjust to the pleural space. As in the radiograph, the angle between 
the lesion and thorax helps when trying to differentiate a pleural from a parenchymal change. 
If the angle between the lesion and thorax wall is sharp, then the change is likely to be a part of 
the lung parenchyma, while if the angle is blunt, then the lesion is more likely to be of pleural 
origin. Nevertheless, CT can also be inconclusive. The findings can be similar to the chest radio-
graph findings, especially when atelectasis or pneumonia are in question, or when a pleural 
collection forms a sharp angle with thorax wall. Free pleural fluid can form sickle-like opacities 
in the lowest and posterior parts of the thorax. Fluid collection that is loculated can be seen as a 
fixed, lenticular opacity. Thickening of the pleura almost invariably points to an exudative effu-
sion [83]. Unreliable signs of pleural invasion are: absence of border area between pleura and 
primary lesion, blunt angle between the tumour and chest wall, and the presence of a pleural 
effusion. A probable sign of pleural invasion is if in addition to rib destruction simultaneously 
the distance between the surface of the tumour and wall of the thorax is less than 3 cm.
The typical features of malignant pleural disease are nodules, irregularity, and pleural thicken-
ing >1 cm. It was found that these pleural characteristics discriminated well between malignant 
and benign disease in a prospective chest radiograph study of 40 patients with suspected malig-
nant effusions, with a sensitivity of 84% and specificity of 100% for malignancy [84]. However, 
pleural thickening alone was not found to be specific as it was found in malignancy as well as in 
empyema. Albeit, the presence of pleural nodules was found to be highly specific, it was found 
Figure 4. Lung cancer followed by an ipsilateral effusion.
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to have only 17% sensitivity—17% of patients with malignant effusion had associated pleural 
nodules. It is interesting that the half of the patient with malignant effusion had no pleural 
abnormalities on CT in this study [85]. In patients with lung cancer, even minimal pleural effu-
sions can represent malignant involvement [86]. CT density coefficient is not specific enough 
to differentiate parenchymal lesion from a solid pleural mass or a serous effusion from blood 
or pus [87]. In these cases, ultrasound is the investigation of choice and has an edge over CT.
4.5.3. Magnetic resonance imaging [MRI]
Pleural effusion can be identified on an MRI scan; however, MRI is not advised for routine 
evaluation of malignant effusions.
Collections of pleural fluid are visible as areas of low intensity signal on T1 images, while 
signal is intensified on T2 images. MRI can sometimes enable the classification of a pleural 
effusion to transudate, chylothorax, empyema, but in essence, the information gained by MRI 
is usually insufficient to be of diagnostic use. However, its ability to produce excellent soft-
tissue contrast can be useful for detailed evaluation of tumour invasion [88]. MRI is superior 
to CT in identification of solitary foci on the chest wall, changes of the endothoracic fascia and 
identifying the invasion of diaphragmatic muscles. MRI can be especially useful in evaluating 
apices of both hemithoraces.
4.5.4. Positron emission tomography with F-18-fluorodexyglucosae [PET]
PET-FDG imaging accurately detected malignant pleural involvement and the presence of 
malignant pleural effusion in 16 out of 18 patients and excluded pleural metastatic involve-
ment or malignant effusion in 16 of 17 patients—sensitivity of 88.8%, specificity 94.1%, and 
accuracy of 91.4%. PET-FDG imaging is a highly reliable and accurate non-invasive test that 
can differentiate benign from malignant pleural effusions and/or pleural involvement in lung 
cancer patients and CT findings of suspected malignant pleural effusion [89]. Nonetheless, 
this form of imaging may not be able to differentiate pleural malignancy from benign inflam-
mation of the pleura, for example, caused by talc pleurodesis [90].
4.5.5. Ultrasound
Thoracic ultrasound can be done with any modern ultrasound machine. Curved ultrasound 
probe 5–7.5 MHz enables the examination of deep structures of the chest wall. Intercostal spaces 
are utilised as an acoustic window [91]. When using high frequency probe of 7.5–10 MHz, pari-
etal and visceral pleura are usually seen as echogenic lines, not thicker than 2 mm (Figure 5). 
Diaphragm is visualised as a bright curved line moving upwards or downwards, depending 
on the respiration phase. High frequency probes improve the resolution in the fields close to 
source of the echo, enabling differentiation of cystic lesions from solid masses. Ultrasound 
properties of pleural fluid are best evaluated by changing the form of the fluid during respira-
tion [10]. Ultrasound discovers the presence of fluid in pleural space with an accuracy varying 
between 87 and 94% [92]. An amount of liquid present in pleural space can be quantified by 
ultrasonographic examination. Calculated amount of liquid is in better correlation with real 
amount of fluid present if it is defined by ultrasonographic examination. Amount of liquid 
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of 1000 ml on radiograms in lateral decubitus correlates to a 30-mm layer of liquid, while the 
same amount of fluid correlates to ultrasonographic thickness of 40 mm [93].
Ultrasound diagnostics is useful in determining a suitable spot for thoracocentesis, especially 
in loculated and small effusions [92, 94, 95]. Ultrasound is also helpful in therapeutic thoraco-
centesis for measuring effusion the depth of an effusion which makes this procedure safer. At 
thoracocentesis, the thickness of pleural liquid must not be less than 10 mm. Complications of 
ultrasound guided thoracocentesis are minimal [94].
Pleural thickenings are presented as constant regions of weak echogenicity. Differentiation of 
pleural thickening from effusion, tumour, and mesothelioma is uncertain. Respiratory depen-
dent configuration change of identified lesion favours a pleural effusion, regular borders 
favour pleural thickening, and irregular borders favour a diagnosis of a tumour [96]. Plaques 
produce the image of focal zones of intensive reflection with dense posterior acoustic shadow 
and usually surrounding non-calcified pleural thickening.
Pleural masses are sonographically presented as masses of unclear limitation, weakly echo-
genic, nodal or linearly disseminated along the pleura. Malignant tumour of pleura can 
infiltrate the chest wall and it leads to poorly visible demarcation of pleural mass from the 
thoracic wall [97]. Pleural thickening over 1 cm brings forward justified suspicion of a malig-
nant tumour. Accompanying pleural effusion is usually visible in a big field which spreads 
locally and is especially emphasised. The effusion is helpful in tumour identification and it 
enables differentiation of parietal from visceral pleura. Visceral pleural thickening is rarely 
Figure 5. ‘Comet tail’ sign.
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seen. In pleural mass, respiratory motions of lungs during the respiratory cycle are reduced. 
Very clear echogenic and irregular reflexes are visible on passing towards the ventilated area 
of lungs.
Metastases might appear as diffuse parietal pleural thickenings. These can be seen as weakly 
echogenic and moderately echogenic structures; they are oval and easily nodal.
4.6. Cytological and pathohistological examination of pleural fluid and pleural 
tissue
The percentage of positive cytological results has a wide range, which depends on the type 
and location of the primary neoplasm, the number of samples being examined, methods and 
way of sample processing. Results of cytological examination depend on pathohistological 
type of tumour, number of prepared samples, length of time sample is kept, and interest of 
cytopathologist.
Malignant cells have several characteristic properties which differentiate them from other 
cells. They can significantly vary in form and size. They are usually large. The diameter of 
the nucleus ranges up to 50 μm and their diameter is significantly bigger than, for example, 
the nucleus of mesothelial cells that are rarely bigger than 20 μm (Figure 6). For comparison, 
small lymphocytes have diameter up to 10 μm. Nucleoli of malignant cells are up to 5 μm in 
size. Nucleoli of non-malignant cells do not exceed 3 μm. Malignant cells have a high nucleo-
cytoplasmic ratio. Morphological analysis itself is not sufficient for differentiation of adeno-
carcinoma cells from, for example, mesothelioma cells. Mesothelioma cells have a tendency 
to make papillary groups, and they are multinuclear, with atypia and cell to cell position. 
Adenocarcinoma cells have a greater tendency to form acini of similar structures. They can 
form big group of cells. Balloon-like cytoplasmic vacuolization is expressed [98].
Groups of 20 or more benign mesothelial cells can sometimes appear bizarre. Large, vacu-
olated cells of adenocarcinoma enable differentiation between these two entities. A small 
number of mitotic figures are often present in benign effusions and the presence of such pic-
ture does not point to malignant disease.
Figure 6. Atypical giant cells in pleural effusion.
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Two most important histochemical tests commonly used are alcian blue staining and periodic 
acid-Schiff. Alcian blue staining enables the detection of acid mucins, which is a specific find-
ing for mesothelioma. Alcian blue staining was positive in 14 out of 19 (73%) patients with 
mesothelioma, while it was negative in all the patients with adenocarcinoma [99]. Periodic acid-
Schiff staining, after diastasis digestion (PAS-D), enables the detection of neutral mucins that 
have a diagnostic value for adenocarcinoma. PAS-D staining was positive in 27 out of 44 (61%) 
patients for adenocarcinoma, while it was negative in all patients with mesothelioma [100].
In differentiation of adenocarcinoma from mesothelioma, a whole palette of monoclonal anti-
bodies is used. The same antibodies are found in the presence of benign mesothelial cells, 
adenocarcinoma, and malignant mesothelioma.
Immunohistochemical staining can be a useful diagnostic tool. Specific markers such as thy-
roid transcription factor 1 exhibit a high specificity for a primary lung carcinoma, whereas 
GATA3 has been advocated as a sensitive and specific immunostain for diagnosis breast can-
cer [101]. Cytological specimens are used for sequencing of mutations of epidermal growth 
factor receptor (EGFR), [102] and with the use of highly sensitive sequencing such as next-
generation sequencing, these markers can be detected even when cytological examination 
affirms a low percentage of malignant cells or even no malignant cells [103].
Pathologist’s challenge can be differentiating mesothelioma from both metastatic adenocar-
cinoma and non-malignant reactive mesothelium. Using a panel of immunohistochemical 
stains is now the standard for diagnosing mesothelioma, including using antibodies that stain 
positively for mesothelioma (WT1, cytokeratin 5/6, calretinin) and those that stain negatively 
(e.g. adenocarcinoma specific stains such as MOC- 31, CEA, Ber-EP4, and B72.3) [104, 105]. 
However, it is of note that pleural liquid mesothelin levels can be elevated in a significant 
number of patients with malignant effusions other than mesothelioma, while mesothelin lev-
els are not elevated in benign effusions. Hence, a high mesothelin level strongly suggests a 
presence of some form of malignancy [106]. The future of diagnosis might include genetic 
analysis—either for microarray characteristic of tumours or for characteristics of malignancy 
(microsatellite, aneuploidy, telomerase DNA methylation, and mutations) [107, 108]. As 
explained earlier, pleural cells genetic testing may lead to therapeutic choices; for example, 
establishing an EGFR mutation in malignant pleural cells can the predict response to pertinent 
EGFR tyrosine kinase inhibitors, like gefitinib or erlotinib [102, 103, 109]. High throughput 
sequencing technology—a by-product of the Human Genome Project, enables rapid sequenc-
ing of either a small percentage of the genome that codes for expressed genes (the exome), or 
the whole genome. As all cancers are unique, the hope is that this could lead to patient-specific 
markers and subsequent therapies—for example, designing specific vaccines that ‘drive’ the 
immune system of the host to attack that patient’s cancer [110].
In previously diagnosed neoplasms, pleural effusion cytology is positive in 50–90% of cases 
[112]. Falsely positive results range from 0 to 3% [111]. The absence of malignant cells in 
pleural effusion does not exclude malignancy and this infers the necessity of repeating the 
cytological investigations.
If repeated cytological analysis is negative, clinical observations and laboratory examinations 
do not point towards a probable aetiology of pleural effusion, and percutaneous blind biopsy 
is indicated (Figure 7).
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Figure 7. Adenocarcinoma invasivum pleurae HG2, NG3 (EMA × 400).
In seven series of malignant pleural effusions published and analysed in the literature (over 
500 recorded cases), cytological analysis of pleural fluid sample had a diagnostic significance 
ranging from 66 [47] to 76% [57]. Pleural biopsy had positive predictive value of 46% [8]. 
Combining of these two procedures, cytological and pathohistological analysis, disease was 
diagnosed in 73% of patients. These data indicate that cytology is the more specific method 
compared to pleural biopsy, while they also suggest that these tests are complementary and 
that small samples given by pleural biopsy can be falsely negative.
In a randomised study that compared CT-guided biopsy with closed pleural biopsy using an 
Abrams needle, CT-guided biopsy was notably more sensitive (87 versus 47%) with a supe-
rior negative predictive value (80 versus 44%) [113]. Thoracoscopy is a procedure that is well 
tolerated and at the same time allows excellent visualisation of the entire pleural surface.
Correct identification of metastatic disease of pleura in nearly 100% of cases is achieved by 
directed pleural biopsies [117]. This technique provides additional advantages, including the 
ability to provide the information about the tumour’s gross appearance, to provide the infor-
mation for staging, to drain the pleural space for talc pleurodesis, to lyse adhesions, and the 
ability to produce large biopsy specimens for genetic and immunohistochemical analysis for 
molecular markers (e.g. EGFR) if needed. In routine examination, pleural effusion analysis by 
electronic microscopy has a slight advantage over cytological examination [115].
5. Possible therapeutic modalities of malignant pleural effusions
Treatment of patients with malignant pleural effusion has to be in accordance with the disease 
prognosis. Asymptomatic patients do not warrant treatment; nevertheless, most patients will 
go on to develop progressive pleural effusions that will elicit symptoms and require treat-
ment. However, some patients will reach a stable state of pleural fluid formation and removal 
and these patients not progress to a symptomatic stage.
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According to therapeutic possibilities, the doctor’s first step is to estimate the patient’s per-
formance status. In order to get a clear answer to the question of should the patient with 
malignant effusion be treated or not treated, the following questions must be answered. Do 
the current symptoms reduce the patient’s quality of life? What was the response of primary 
tumour to radiotherapy or chemotherapy? What is the performance status? What is the 
expected survival time? What was the patient’s response to initial thoracocentesis? What is 
the liquid reaccumulation rate after evacuating thoracocentesis? For how long was the patient 
asymptomatic after thoracocentesis? Did lungs re-expand after drainage? Is the patient in a 
condition to tolerate intrapleural sclerotherapy?
If one is to follow this line of thought and principle, cooperation with oncologist, cardio-tho-
racic surgeon, radiotherapist, and everyone involved in the patient’s treatment is necessary.
After diagnostic thoracocentesis is performed, therapeutic thoracocentesis follows (without 
intrapleural medication) which probably will not result in long-term control of pleural effu-
sion [79, 116]. Possible complications of repeated thoracocentesis are secondary infections, 
loss of proteins, artificial pneumothorax, effusion loculation, and trapped lung.
5.1. Significance of specific oncological treatment
One of the important principles of oncological treatment is primary implementation of radio 
and/or chemotherapy. In cancers which have a high probability of being highly sensitive to 
systemic chemotherapy, for example, lymphoma, chemotherapy is the treatment of choice 
[79]. Of course, thoracocentesis is necessary in the initial phase of diagnostics and treatment, 
for both cytological examination and alleviating symptoms of respiratory distress.
Patients with an effusion and a tumour that is refractory to chemotherapy should have tho-
racontesis performed every 3-4 days for symptomatic relief. In NSCLS, colon and pancreatic 
cancer, favourable effects of primary systemic chemotherapy and/or radiotherapy are not 
expected. Intrapleural therapy will probably be indicated for these patients.
5.2. Treatment modalities—therapeutic approach
Moribund patients and patients in the preterminal phase of disease, with the symptoms of 
respiratory distress thoracocentesis is an urgent therapeutic procedure for alleviating cur-
rent symptomatology. Aggressive therapy is not recommended in such patients. In view of 
possible complications during repeated thoracocentesis, a certain number of doctors reserve 
thoracocentesis only for moribund patients as a type of a short-term symptomatic therapy.
Patients who have a good performance status and longer survival time is expected, che-
motherapy and/or radiotherapy is administrated after thoracocentesis. Generally, systemic 
chemotherapy produces disappointing results when it comes to control of malignant pleural 
effusion. Since the adverse effects from radiation pneumonitis outweigh the possible benefits 
of therapy, hemithorax radiation is contraindicated in malignant pleural effusion from lung 
cancer as a rule (Figure 8).
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Drainage or intrapleural therapy is indicated if previous therapeutic protocols produce no 
results, that is, if they did not enable the control of pleural fluid production. Reaccumulation 
of larger amount of liquid leads to respiratory distress and/or worsening of clinical picture.
Pleurectomy, shunts, and other aggressive surgical interventions are reserved for patients refrac-
tive to intrapleural therapy. Pleurectomy and/or pleural abrasion are highly effective in oblitera-
tion of pleural space and in malignant pleural effusion control [117]. Therefore, this procedure 
is reserved for patients who have a reasonably long expected survival time and are in good 
general condition or who have failed a sclerosing agent therapeutic procedure. Pleuroperitoneal 
shunt has been demonstrated to be both safe and effective [118]. The shunt can be especially 
beneficial in refractory chylothorax where it allows recirculation of chyle [119]. Hyperthermic 
intrathoracic chemotherapy perfusion (HITHOC) combined with cytoreductive surgery can be 
performed in selected patients with acceptable mortality and morbidity rates [120].
5.3. Use of thoracic drain
Primary therapeutic task for treatment of patients with malignant effusion is alleviating 
dyspnoea. Reaccumulation of fluid sometimes can be controlled by intrapleural instillation 
of medication. In controlling the usual techniques of thoracocentesis, needle aspiration, and 
drainage are rarely efficient [79]. Treatment is basically palliative, disregarding the stage of 
disease and condition of the patient. Drainage postpones respiratory distress, but it does not 
prevent reaccumulation of liquid, dyspnoea, and pleural pain. Therefore, all patients with 
Figure 8. Diagnostic and therapeutic algorithm in malignant pleural effusions.
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notable symptomatology, except moribund and those patients in preterminal stage of disease, 
are recommended to have drainage of pleural space with instillation of therapeutic solution. 
Intrapleural therapy often produces satisfactory outcomes with in regard of long term pallia-
tion of respiratory symptoms by reducing or eliminating pleural liquid formation.
In loculated effusions, drainage is not successful. This is due to the fact that the lung never 
re-expands sufficiently so that visceral and parietal pleura are in contact. In this case, intra-
pleural therapy is not recommended.
Instillation of thoracic drain is a safe and successful surgical procedure enabling at the same 
time diagnostics and treatment of malignant pleural effusion. If it is performed correctly, the 
method is relatively painless.
After placing the drain, it is necessary to perform control radiographs in order to check the 
correct position of the drain, exclude pneumothorax, establish lung expansion, and amount 
of liquid that is possibly retained.
Lung expansion is necessary to achieve in order to close the space previously filled with liq-
uid and to bring pleural surfaces into contact.
Failure of pleurodesis is associated with abnormal lung expansion that is detected with pleu-
ral manometry. A pleural space elastance greater than 19.0 cm H
2
O/L during the evacuation of 
first 500 ml of pleural liquid was found to predict 100% pleurodesis failure at 1 month [121]. 
Lung expansion abnormalities detected during later stages are indicative of immediate or 
delayed pleurodesis outcomes.
Prerequisite for pleurodesis is that the effusion is not loculated, that patient has a good 
performance status and that expected survival time is longer than 4 weeks. After adequate 
evacuation of liquid, medicines are instilled into pleural space by bolus. Whether the 
procedure is done with or without active suction, fast decompression should be avoided. 
Consequences of fast decompression are severe pain, pulmonary shock, mediastinal shift, 
and pulmonary oedema of the re-expanded lung. If the effusion is massive, 1000–1500 ml 
can be evacuated. Drained should be intermittently clammed, especially in the early phase 
of suction. This way, hemodynamic stabilisation of patient is ensured. Drainage is continu-
ous while daily amount of aspirated content is higher than 100 ml. By irritating pleura and 
lungs, every drain will produce around 50 ml of pleural liquid during 24 h. Drainage gives 
satisfactory results in less than 20% of patients [69, 116]. Nevertheless, pleurodesis in an 
outpatient setting using small-bore catheters can be successfully performed with decreased 
cost and morbidity.
The utilisation of indwelling catheters [Denver Biomaterials, Golden, PleurX, Colorado] has 
attained popularity due to it being an outpatient procedure, which allows the patient and 
family to manage the pleural effusion in a timely fashion at home. For symptomatic refractory 
or recurrent malignant pleural effusion, these catheters have grown to be the mainstay of 
treatment in most centres in the United States. This is due to their ability to successfully pal-
liate the symptoms of dyspnoea regardless of the presence of lung entrapment. Spontaneous 
pleurodesis is developed by approximately 50% of patients by 2 months [122, 123].
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5.4. Medicine choice for intrapleural therapy
It is presumed that medications such as tetracyclines, talc, and nitrogen mustard, etc. cause 
inflammation of pleural surfaces. Inflammation leads to obliteration of pleural space disabling 
reacummulation of liquid [pleurodesis]. The mechanism of action of 5-fluorouracil effect is 
even less clear. Agents like cisplatin and cytosine arabinoside locally achieve high concentra-
tions; thus, they are assumed to have a direct cytoreductive effect [116].
Choice of medication for pleurodesis partly depends on clinical, and partly on non-clinical 
parameters.
5.4.1. Nitrogen mustard
Nitrogen mustard (mechlorethamine) has been used in intrapleural therapy since 1949 and it 
is one of the first medications used in control of malignant pleural effusions [124]. Medicine 
efficiency is different and is accompanied by a large number of side effects such as chest pain, 
nausea, and vomiting [124, 125].
5.4.2. Talc
Talc is one of the oldest and most efficient medicines [79, 125]. Talc is instilled into the pleural 
space as a suspension or powder (Figure 9). Insufflation of talc powder has proven to be 
more efficient than instillation of the suspension [125]. Following talc poudrage and slurry, 
fever is a common occurrence, occurring 16–69% of the time. Complications that have also 
been reported with talc usage include arrhythmia, empyema, respiratory failure including 
pneumonitis, and adult respiratory distress syndrome (ARDS).
5.4.3. Quinacrine
Quinacrine is an antimalarial medication which has been recommended in therapy of malig-
nant effusions for a period of time. Its use is completely abandoned now [79].
5.4.4. Biological agent—corynebacterium parvum
Biological agent—corynebacterium parvum in dose from 5 to 10 mg was promising at first; 
however, randomised study which compared its efficiency with efficiency of tetracycline did 
not show a statistically significant efficiency [126, 127].
5.4.5. Tetracycline
Tetracycline is a very popular medicine in intrapleural therapy because of its efficiency, 
affordability, and ease of use. Recommended dose for instillation is between 500 mg and 
3 g of diluted tetracycline in 50–100 ml of normal saline [114, 127]. The most common side 
effects, in about 30–40% patients, are fever and moderate to severe chest pain which requires 
premedication [79]. Tetracycline is efficient in prevention of pleural effusion recurrence as 
well. Crucial factor for treatment success is fast and complete dispersion of tetracycline in 
pleural space [125].
Lung Cancer - Strategies for Diagnosis and Treatment68
5.4.6. Bleomycin
Bleomycin is an antitumor, antibiotic producing significant results in prevention of pleural 
liquid reaccumulation [128]. Usual dose is 60 U in 100 ml D5W or normal saline [129, 130]. 
Systemic reabsorption is limited. About 40–45% of medicine is resorbed via pleura. This dose 
of medicine does not supress the bone marrow; thus, bleomycin can be used simultaneously 
with chemotherapy and radiotherapy and it can be used in patients that suffer from myelo-
suppresion [129].
In prevention of malignant pleural effusion, recurrence bleomycin is more efficient than tetracy-
cline. Average time of effusion recurrence after tetracycline therapy (dose of 1 gram) was 32 days 
and 46 days for bleomycin (dose of 60 U) [129]. Series of three to four daily instillations of bleomy-
cin is used in refractory effusions with a reduction in dosing from 60 to 30 U [131] is recommended.
5.4.7. Other medicines
Other medicines used for pleurodesis are thiotepa and 5-fluorouracyl, but they are less effi-
cient than above mentioned medications. It is assumed that NaOH implementation achieves 
chemical pleuritis [132]. Doxorubicin has a similar effect to nitrogen mustard [121].
After pleurodesis, reaccumulation of liquid occurs in around 20–30% patients. If this is a small 
amount of fluid and is well tolerated by the patient, further treatment is usually not necessary.
The most efficacious methods in control of the effusion are pleural abrasion, chest tube drain-
age with sclerosing agent instillation, and pleurectomy. Mixed intravenous and intrapleural 
chemotherapy, with air therapy has produced response in 55% of patients, complete remission 
has resulted in 7%, partial remission in 48%, in 22% disease stabilisation has been achieved, 
and disease progression has been recorded in 22% of patients [133].
5.5. Therapy associated pain
After intrapleural administration of sclerotherapy, pain might occur. After drainage of 
15–20 ml, 2% lidocaine is instilled via drain or catheter. The patient needs to breathe deeply and 
cough mildly for better distribution of anaesthetic over the surface of pleural space. Five to ten 
minutes before tetracycline is intravenously injected, 75–150 μg fentanyl is administrated, and 
Figure 9. CXR before and after pleurodesis.
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5–10 mg of morphine is given after that. Fentanyl acts very quickly, as morphine takes over the 
extended analgesic effect. Fentanyl is slowly injected, over 5–7 minutes. If an unwanted reaction 
to fentanyl is expected, naloxone is given. Doctor must make sure that drain or flexible cath-
eter is vertical and that intrapleural agent from the drain interflows into pleural space. In the 
analgesic therapy, results are achieved with less strong medications; therefore, premedication 
with morphine 10 mg or meperidine 75–100 mg intramuscularly or subcutaneously is recom-
mended. Just before tetracycline solution instillation, 20 ml of 2% lidocaine is given intrapleu-
rally. Morphine, fentanyl as well as other analgesics can have a depressive effect on respiratory 
centre and therefore, these principles of pain therapy cannot be applied in elderly patients, 
patients who are predisposed to respiratory depression and those with a bad general condition.
6. Conclusion
PMPE were equally present in all pathohistological types of lung cancer, while MPE were 
most common in lung adenocarcinoma. The diagnostic yield of pleural fluid cytology and 
closed pleural biopsy combined was more than 90%. Most commonly used therapeutic pro-
cedures were thoracocentesis and pleurodesis. PMPE were not a contraindication for explor-
ative thoracotomy.
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